The execs at Haleon, a huge multinational consumer products company, ought to take a good look in the mirror. That is, unless ...

Look no further than GlaxoSmithKline shedding its consumer health arm to form Haleon ... And with talent shortage already a challenge in healthcare and pharma, it’s also important to align ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

Annual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...

GSK announced several transactions involving the vesting and sale of ordinary shares under its Performance Share Plan and Deferred Investment Award Programme. The transactions involve key executives, ...

GSK's Q4 EPS and sales beat estimates Shares ... on sales of 7.75 billion pounds expected by analysts in an LSEG poll. Healthcare & Pharmaceuticalscategory Indonesia launches $183 million free ...

GSK's consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 billion).

Blenrep trial shows 42% lower mortality risk; peak-year sales expected over £3 billion. Depemokimab data reveals 72% reduction in hospitalizations; projected sales hit £4 billion. Brand New ...

CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...

GSK plans to buy back £2 billion (S$3.4 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline. The British drugmaker boosted its 2031 sales forecast to over ...

which was created by the merger of GSK (GSK.L), opens new tab and Pfizer's consumer healthcare businesses in 2019. It was spun off from the British drugmaker in 2022. Pfizer, which will remain ...